CrownBio provides an integrated platform for preclinical drug development and expert consultation that will enable your clear next-step decision:

×

Select qualified Crohn’s disease and Ulcerative Colitis lead agents.

Determine efficacy and response to treatment.

Preclinical models with diverse mechanisms in each model that capture many of the key characteristic clinical and pathologic features of IBD including:

• gut epithelial/barrier defect model
• innate and regulatory cell mediated model

Gut epithelia/barrier defect mouse model – DSS-induced colitis

Dextran sulfate sodium (DSS) is a sulfated polysaccharide with variable molecular weights. Administration of DSS in the drinking water causes activation of neutro¬phils and macrophages that result in a compromised mucosal barrier function.

In the Acute DSS IBD model, mice are given DSS in their drinking water for 7 days, followed by several days of tap water to induce a Th2 UC-like inflammation in the colon.

Major endpoints:

• Bloody stool/diarrhea
• Weight loss
• Colon weight/length.
  • Disease activity index
  • Muscosal integrity

Histopathological assessment:

• Board Certified Veterinary Pathologist.

Innate and regulatory cell mediated mouse model – T cell transfer

CD4+CD45RB_hi cells are isolated from spleens of BALB/c mice and transferred intoSCID recipients. Clinical disease develops from 3 weeks post-transfer, and peaks at 5-6 weeks.

• Weight loss
• Diarrhea
• Colon weight/length
• Disease activity index
• Muscosal integrity

Histopathological assessment:

• Board Certified Veterinary Pathologist